MiR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 957-964

  She, Xiaoling ^a,b   Yu, Zhibin ^b,c   Cui, Yulong ^a   Lei, Qianqian ^b,c   Wang, Zeyou ^b,c   Xu, Gang ^b,c   Xiang, Juanjuan ^b   Wu, Minghua ^b,c   Li, Guiyuan ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c The Center for Skull Base Surgery and Neurooncology   (China)

Author keywords

Cytoskeleton; F actin; Glioblastoma; miR 128; miR 149; Temozolomide

Indexed keywords

MICRORNA; PROTEIN MIR 128; PROTEIN MIR 149; PROTEIN RAP1B; RAP1 PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; MIRN128 MICRORNA, HUMAN; MIRN149 MICRORNA, HUMAN; RAP PROTEIN; RAP1B PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; CYTOSKELETON; DOWN REGULATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOSKELETON; DACARBAZINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICRORNAS; RAP GTP-BINDING PROTEINS; UP-REGULATION;

EID: 84921628426     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3318     Document Type: Article

References (40)

1. Pichiorri F, Palmieri D, De Luca L, et al: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 210: 951-968, 2013.
2. Pizzini S, Bisognin A, Mandruzzato S, et al: Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 14: 589, 2013.
3. Yang J, Zhao H, Xin Y and Fan L: MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem 115: 987-995, 2013.
4. Chen L, Zhang Y, Yang J, Hagan JP and Li M: Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta 1836: 158-165, 2013.
5. Chou KN, Lin YC, Liu MY and Chang PY: Temozolomiderelated acute lymphoblastic leukemia with translocation (4;11) (q21;q23) in a glioblastoma patient. J Clin Neurosci 21: 701-704 2013.
6. Danson SJ and Middleton MR: Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 1: 13-19, 2001. (Pubitemid 34679390)
7. Stupp R, Gander M, Leyvraz S and Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2: 552-560, 2001. (Pubitemid 33586868)
8. Wong STS, Zhang XQ, Zhuang JTF, Chan HL, Li CH and Leung GKK: MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 32: 2835-2841, 2012.
9. Shi L, Chen JA, Yang JA, Pan TH, Zhang SG and Wang ZM: MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352: 255-264, 2010.
10. Qian XM, Ren Y, Shi ZD, et al: Sequence-dependent synergistic inhibition of human glioma cell lines by combined temozolomide and miR-21 inhibitor gene therapy. Mol Pharm 9: 2636-2645, 2012.
11. Ujifuku K, Mitsutake N, Takakura S, et al: miR-195, miR-455-3p and miR-10a* are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296: 241-248, 2010.
12. Slaby O, Lakomy R, Fadrus P, et al: MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 57: 264-269, 2010.
13. Shi L, Zhang SG, Feng K, et al: MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 40: 119-129, 2012.
14. Li D, Chen P, Li XY, et al: Grade-specific expression profiles of miRNAs/mRNAs and docking study in human grade I-III astrocytomas. OMICS 15: 673-682, 2011.
15. Wittchen ES, Aghajanian A and Burridge K: Isoform-specific differences between Rap1A and Rap1B GTPases in the formation of endothelial cell junctions. Small GTPases 2: 65-76, 2011.
16. Nuovo GJ: In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods 44: 39-46, 2008.
17. Evangelisti C, Florian MC, Massimi I, et al: MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 23: 4276-4287, 2009.
18. Zhang Y, Chao T, Li R, et al: MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med 87: 43-51, 2009.
19. Costa PM, Cardoso AL, Nobrega C, et al: MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma. Hum Mol Genet 22: 904-918, 2013.
20. Khan AP, Poisson LM, Bhat VB, et al: Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9: 298-312, 2010.
21. Weiss GJ, Bemis LT, Nakajima E, et al: EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19: 1053-1059, 2008. (Pubitemid 351796329)
22. Kotani A, Ha D, Schotte D, den Boer ML, Armstrong SA and Lodish HF: A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 9: 1037-1042, 2010.
23. Zhu Y, Yu F, Jiao Y, et al: Reduced miR-128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 17: 7105-7115, 2011.
24. Shi ZM, Wang J, Yan Z, et al: miR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS One 7: e32709, 2012.
25. Lin RJ, Lin YC and Yu AL: miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog 49: 719-727, 2010.
26. Jin L, Hu WL, Jiang CC, et al: MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 108: 15840-15845, 2011.
27. Wang Y, Zheng XS, Zhang ZY, et al: MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS One 7: e41693, 2012.
28. Tu HF, Liu CJ, Chang CL, et al: The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS One 7: e51606, 2012.
29. Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG and Sun BM: MicroRNA-149 inhibits proliferation and invasion of glioma cells via blockade of AKT1 signaling. Int J Immunopathol Pharmacol 25: 871-881, 2012.
30. Tang HL, Wang ZY, Liu XP, et al: LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 12: 1032-1042, 2012.
31. Guo Y, Yan KP, Fang JS, Qu Q, Zhou M and Chen FH: Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res 32: 41, 2013.
32. Pellegrino L, Stebbing J, Braga VM, et al: miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts. Nucleic Acids Res 41: 5400-5412, 2013.
33. Avellino R, Carrella S, Pirozzi M, et al: miR-204 targeting of Ankrd13A controls both mesenchymal neural crest and lens cell migration. PLoS One 8: e61099, 2013.
34. Bockhorn J, Yee K, Chang YF, et al: MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 137: 373-382, 2013.
35. Bertoni A, Tadokoro S, Eto K, et al: Relationships between Rap1b, affinity modulation of integrin αIIbß3, and the actin cytoskeleton. J Biol Chem 277: 25715-25721, 2002. (Pubitemid 34951891)
36. Malchinkhuu E, Sato K, Maehama T, et al: Role of Rap1B and tumor suppressor PTEN in the negative regulation of lysophosphatidic acid-induced migration by isoproterenol in glioma cells. Mol Biol Cell 20: 5156-5165, 2009.
37. Vega FM and Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett 582: 2093-2101, 2008.
38. de Toledo M, Anguille C, Roger L, Roux P and Gadea G: Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One 7: e48344, 2012.
39. Feng H, Hu B, Liu KW, et al: Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 121: 4670-4684, 2011.
40. Fortin Ensign SP, Mathews IT, Eschbacher JM, Loftus JC, Symons MH and Tran NL: The Src homology 3 domaincontaining guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2. J Biol Chem 288: 21887-21897, 2013.